Company ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed London S.E. Other stock markets 04:24:31 2024-04-23 am EDT			5-day change	1st Jan Change
2.388 ^GBX	+0.13%		+5.67%	+43.26%

Apr. 02	Immupharma jumps amid new IP strategy for P140 technology platform	AN
Apr. 02	ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	CI

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Number of employees: 13

Managers	Title	Age	Since
Tim McCarthy McCarthy CEO	Chief Executive Officer	68	15-09-29
Timothy Franklin COO	Chief Operating Officer	60	20-10-31
Lisa Baderoon BRD	Director/Board Member	57	12-02-28

Members of the board	Title	Age	Since
Tim McCarthy McCarthy CEO	Chief Executive Officer	68	15-09-29
Timothy Franklin COO	Chief Operating Officer	60	20-10-31
Lisa Baderoon BRD	Director/Board Member	57	12-02-28
Laurence Reilly BRD	Director/Board Member	42	23-08-10
Sebastien Goudreau BRD	Director/Board Member	-	23-08-10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	416,437,265	237,368,751 ( 57.00 %)	0	57.00 %

Name	Equities	%	Valuation
KW Investment Management Ltd. 17.12 %	71,294,000	17.12 %	2 M p
Lanstead Capital Investors LP 15.89 %	66,161,974	15.89 %	2 M p
Hargreaves Lansdown Asset Management Ltd. 4.900 %	20,404,000	4.900 %	547 643 p
Chelverton Asset Management Ltd. 3.602 %	15,000,000	3.602 %	402 600 p
HSBC Global Asset Management (UK) Ltd. 2.666 %	11,103,000	2.666 %	298 005 p
IG Markets Ltd. 2.531 %	10,542,000	2.531 %	282 947 p
Bank J. Safra Sarasin AG (Investment Management) 0.7840 %	3,264,696	0.7840 %	87 624 p
Clearstream Banking SA 0.6729 %	2,802,000	0.6729 %	75 206 p
Consorsbank 0.6330 %	2,636,000	0.6330 %	70 750 p
HSBC Bank Plc (Market-Maker) 0.6147 %	2,560,000	0.6147 %	68 710 p

Name	Equities	%	Valuation
Incanthera Plc 10.75%	9,903,349	10.75%	1,876,586 $

ImmuPharma Plc

One Bartholomew Close

EC1A 7BL, London

+44 20 7206 2650

http://www.immupharma.com

Name	Category and Sector
IMMUPHARMA PLC	Pharmaceuticals: Other

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUPHARMA PLC	+43.26%	12.25M
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+45.83%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research